Literature DB >> 11400253

A framework for cost-effectiveness analysis from clinical trial data.

A O'Hagan1, J W Stevens.   

Abstract

We present a general Bayesian framework for cost-effectiveness analysis (CEA) from clinical trial data. This framework allows for very flexible modelling of both cost and efficacy related trial data. A common CEA technique is established for this wide class of models through linking mean efficacy and mean cost to the parameters of any given model. Examples are given in which efficacy may be measured as a continuous, binary, ordinal or time-to-event outcome, and in which costs are modelled as distributed normally, log-normally, as a mixture or non-parametrically. A case study is presented, illustrating the methodology and illuminating the role of prior information. Copyright 2001 John Wiley & Sons, Ltd.

Mesh:

Year:  2001        PMID: 11400253     DOI: 10.1002/hec.617

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  17 in total

1.  Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).

Authors:  P W Serruys; P A Lemos; B A van Hout
Journal:  Heart       Date:  2004-09       Impact factor: 5.994

2.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

Review 3.  The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis.

Authors:  Grant H Skrepnek
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes.

Authors:  Gianluca Baio; Pierluigi Russo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

5.  The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.

Authors:  Joan Rovira; Guillermina Albarracin; Luis Salvador; Javier Rejas; Eduardo Sánchez-Iriso; Juan M Cabasés
Journal:  Community Ment Health J       Date:  2012-04-08

6.  Bayesian decision analysis for choosing between diagnostic/prognostic prediction procedures.

Authors:  John Kornak; Ying Lu
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

7.  Multicriteria optimization model for the study of the efficacy of skin antiaging therapy.

Authors:  Maria Crişan; Guido Cappare; Luciana Neamţiu; Ioana Chiorean; Liana Lupşa; Diana Crişan; Radu Badea
Journal:  Comput Math Methods Med       Date:  2012-02-28       Impact factor: 2.238

8.  Medicoeconomic index for photo-induced skin cancers.

Authors:  Ioana Chiorean; Liana Lupşa; Luciana Neamţiu; Maria Crişan
Journal:  Comput Math Methods Med       Date:  2011-11-01       Impact factor: 2.238

9.  Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.

Authors:  Jeffrey S Hoch; Marie Antoinette Rockx; Andrew D Krahn
Journal:  BMC Health Serv Res       Date:  2006-06-06       Impact factor: 2.655

10.  The probability of cost-effectiveness.

Authors:  Anthony O'Hagan; John W Stevens
Journal:  BMC Med Res Methodol       Date:  2002-03-11       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.